4414-87-3

Usage

Uses

Used in Pharmaceutical Synthesis:
1H-Pyrrolo[2,3-b]pyridine-3-acetonitrile is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of a wide range of bioactive molecules, making it a valuable asset in the development of new drugs.
Used in Chemical and Biochemical Research:
1H-Pyrrolo[2,3-b]pyridine-3-acetonitrile is used as a research tool in various chemical and biochemical studies. Its presence in experiments can help researchers understand the interactions and reactions of different molecules, contributing to the advancement of scientific knowledge in these fields.

InChI:InChI=1/C9H7N3/c10-4-3-7-6-12-9-8(7)2-1-5-11-9/h1-2,5-6H,3H2,(H,11,12)

Upstream product

• 5654-92-2 7-azagramine 
• 143-33-9 sodium cyanide 
• 77-78-1 dimethyl sulfate 
• 271-63-6 7-Azaindole 
• 773837-37-9 sodium cyanide 
• 50-00-0 formaldehyd 
• 7677-24-9 trimethylsilyl cyanide 
• 87358-28-9 N,N,N-trimethyl-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanaminium iodide 

Downstream Products

• 4649-12-1 2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-ethylamine 
• 1912-42-1 (1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid 
• 1313530-14-1 2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-oxo-3-(3,4,5-trimethoxyphenyl)propanenitrile 
• 1313529-93-9 5-amino-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazole 
• 1313530-15-2 5-amino-N-methyl-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazole-1-carbothioamide 
• 1313530-16-3 1-[5-amino-4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-1-yl]ethanone 
• 1313530-17-4 2,2,2-trifluoro-N-(4-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3-(3,4,5-trimethoxyphenyl)-1H-pyrazol-5-yl)acetamide 
• 1313530-18-5 8-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-7-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a][1,3,5]triazine-2,4(1H,3H)-dione 
• 1313530-19-6 3-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5,7-bis(trifluoromethyl)-2-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidine 
• 5654-93-3 3-methyl-1H-pyrrolo<2,3-b>pyridine 
• 626605-11-6 4-{1-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-1'-triisopropylsilanyl-1'H-[3,3']bipyrrolyl-2,5-dione 
• 626605-16-1 3-{1-[3-(tert-butyldiphenylsilanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-4-dibenzofuran-4-yl-pyrrole-2,5-dione 
• 626605-32-1 3-{1-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-4-(4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyridin-2-yl)-pyrrole-2,5-dione 
• 626605-20-7 3-{1-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}-4-quinolin-8-yl-pyrrole-2,5-dione 

Relevant academic research and scientific papers

Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131)

Selective targeting of cancer cells over normal cells is a key objective of targeted therapy. However few approaches achieve true mechanistic selectivity resulting in debilitating side effects and dose limitation. In this work we describe the discovery of A131 (4a), a new agent with an unprecedented dual mechanism of action targeting both mitosis and autophagy. Compound 4a was first identified in a phenotypic screen in which HeLa cells treated with 4a manifested mitotic arrest along with formation of multiple vesicles. Further investigations showed that 4a causes an increase in mitotic marker pH3 and autophagy marker LC3. Importantly 4a induces cell death in cancer cells while sparing normal cells which regrow after 4a is removed. Dual activities against pH3 and LC3 markers are required for cancer cell selectivity. An extensive SAR investigation confirmed 4a as the optimal dual inhibitor with potency against a panel of 30 cancer cell lines (average antiproliferative GI50 1.5 μM). In a mouse model of paclitaxel-resistant colon cancer, 4a showed 74% tumor growth inhibition when administered at a dose of 20 mg/kg IP twice a day.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of BAF complex related disorders.

FXR MODULATORS AND METHODS OF THEIR USE

The present disclosure is directed to modulators of farnesoid X receptor. Methods of making and using these modulators is also described.

New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations

Members of the kinesin superfamily are involved in key functions during intracellular transport and cell division. Their involvement in cell division makes certain kinesins potential targets for drug development in cancer chemotherapy. The two most advanc

Use of derivatives of indoles for the treatment of cancer

The present invention relates to the use of derivatives of indoles having a general formula (I) as follow: for the manufacture of a pharmaceutical composition intended for the treatment of cancer.

Synthesis of novel 3,4-diaryl-5-aminopyrazoles as potential kinase inhibitors

Synthesis of a diverse series of novel 3,4-diaryl-5-aminopyrazoles as candidates in the development of new protein kinase inhibitors is reported for the first time. In the course of a wider study into bisindolylmaleimide (BIM) derivatives, we examined a novel 5-aminopyrazole heterocyclic moiety as a structural analogue of the highly potent VEGF-R2/3 inhibitor pyrrole-2-one (8). The versatile nature of this pharmacophore allows considerable scope for derivatisation and hence exploration of structure activity relationships. Consequently, a variety of structural modifications were used in order to diversify the aminopyrazole ring substituents. Bicyclic derivatives of the parent aminopyrazoles (11, 12) were also synthesised as a means of probing the kinase active site, leading to formation of complex planar pyrimidine moieties. This work provides the framework for new explorations into kinase inhibition and critical investigations into selectivity of inhibitory activity.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl] acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl] acetic acid aldose reductase inhibitors. The lead candidate, [6-methyl-3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyri din-1-yl]acetic acid example 16, inhibits aldose reductase with an IC50 of 8 nM, while being inactive against aldehyde reductase (IC50 > 100 μM), a related enzyme involved in the detoxification of reactive aldehydes.

Diheterocyclic styryl nitriles

Disclosed herein are compounds of the formula: STR1 where Ar1 and Ar2 are, independently, pyridinyl, quinolinyl, 1,4-benzodioxanyl, dihydro-1,4-benzodioxanyl, pyrrolyl, azaindolyl or carbazolyl, or a pharmaceutically acceptable salt thereof, which are useful as inhibitors of smooth muscle cell proliferation.